

Mark A Preston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11567454/publications.pdf>

Version: 2024-02-01

116
papers

2,898
citations

159585
30
h-index

182427
51
g-index

117
all docs

117
docs citations

117
times ranked

4795
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279.	1.3	2
2	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	1.9	12
3	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 485-485.	1.6	0
4	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	1.6	7
5	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	2.5	3
6	Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).. <i>Journal of Clinical Oncology</i> , 2022, 40, e17051-e17051.	1.6	0
7	Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. <i>European Urology</i> , 2022, 82, 247-251.	1.9	8
8	Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5111-TPS5111.	1.6	0
9	Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies. <i>Cancer Research</i> , 2022, 82, 5893-5893.	0.9	0
10	Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 432-432.	1.6	0
11	Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.	1.6	4
12	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, 32-32.	1.6	2
13	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17003-e17003.	1.6	0
14	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 61-61.	0.4	2
15	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61.	0.4	180
16	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	1.0	3
17	Is Vasectomy a Cause of Prostate Cancer?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 5-6.	6.3	2
18	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 74-80.	3.1	8

#	ARTICLE	IF	CITATIONS
19	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	6.4	59
20	AUTHOR REPLY. <i>Urology</i> , 2020, 140, 121.	1.0	0
21	The association of diabetes with risk of prostate cancer defined by clinical and molecular features. <i>British Journal of Cancer</i> , 2020, 123, 657-665.	6.4	31
22	Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 290-296.	1.0	1
23	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020, 78, 637-639.	1.9	5
24	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 140, 115-121.	1.0	6
25	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5503-5503.	1.6	7
26	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439.	1.6	101
27	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507.	1.6	12
28	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9-9.	1.6	10
29	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19390-e19390.	1.6	0
30	Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 540-540.	1.6	0
31	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. <i>Journal of Clinical Oncology</i> , 2020, 38, 39-39.	1.6	0
32	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 280-280.	1.6	0
33	Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 474-474.	1.6	0
34	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	2.8	27
35	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e488-e493.	1.9	11
36	Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. <i>European Urology Oncology</i> , 2019, 2, 126-134.	5.4	11

#	ARTICLE	IF	CITATIONS
37	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	5.4	6
38	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	1.9	43
39	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. European Urology, 2019, 75, 649-658.	1.9	82
40	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal of Urology, 2019, 37, 2059-2065.	2.2	40
41	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. Cancer, 2019, 125, 1319-1329.	4.1	20
42	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU International, 2019, 124, 40-46.	2.5	17
43	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Journal of Urology, 2019, 201, 721-727.	0.4	15
44	Diagnostic performance of ¹⁸ F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of ¹⁸ F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2019, 37, 5012-5012.	1.6	3
45	Genomic profiling of variant urinary tract tumor histologies.. Journal of Clinical Oncology, 2019, 37, 450-450.	1.6	0
46	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience.. Journal of Clinical Oncology, 2019, 37, e16037-e16037.	1.6	0
47	Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care, 2018, 41, 1432-1437.	8.6	43
48	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	1.6	21
49	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.. European Urology, 2018, 73, e96-e97.	1.9	0
50	Bladder cancer local staging: multiparametric MRI performance following transurethral resection. Abdominal Radiology, 2018, 43, 2412-2423.	2.1	22
51	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	1.9	20
52	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	2.5	30
53	Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab. European Urology, 2018, 73, 372-373.	1.9	5
54	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	1.9	17

#	ARTICLE	IF	CITATIONS
55	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70. European Urology, 2018, 73, e100-e101.	1.9	1
56	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	1.9	62
57	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	3.0	2
58	Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 979-982.	2.5	13
59	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.6	2
60	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	2.2	12
61	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	5.4	59
62	A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. Journal of Clinical Oncology, 2018, 36, TPS5092-TPS5092.	1.6	4
63	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. Journal of Clinical Oncology, 2018, 36, 679-679.	1.6	0
64	Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.. Journal of Clinical Oncology, 2018, 36, 677-677.	1.6	0
65	The prognostic impact of a negative confirmatory biopsy in men on active surveillance for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 76-76.	1.6	0
66	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. Journal of Clinical Oncology, 2018, 36, 465-465.	1.6	0
67	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. Journal of Clinical Oncology, 2018, 36, 492-492.	1.6	0
68	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. Journal of Clinical Oncology, 2018, 36, 4539-4539.	1.6	0
69	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	1.6	104
70	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. Journal of Urology, 2017, 198, 297-304.	0.4	35
71	Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. European Urology, 2017, 72, 821-827.	1.9	44
72	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	1.9	110

#	ARTICLE	IF	CITATIONS
73	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	12.8	106
74	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1075-1075.	0.4	0
75	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355.	4.1	138
76	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	1.9	39
77	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 305-305.	1.6	63
78	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332.	1.6	1
79	Post-orchietomy adjuvant therapy versus surveillance for stage IS testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 406-406.	1.6	0
80	Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 331-331.	1.6	0
81	Characterizing the costs of complications after cystectomy: Can we target the primary drivers?. <i>Journal of Clinical Oncology</i> , 2017, 35, 304-304.	1.6	0
82	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16001-e16001.	1.6	0
83	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , 2016, 118, 286-297.	2.5	39
84	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	1.6	174
85	Moving Towards Widespread Implementation of Enhanced Recovery Protocols for Radical Cystectomy. <i>European Urology</i> , 2016, 70, 1004-1005.	1.9	1
86	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. <i>Cancer Prevention Research</i> , 2016, 9, 933-941.	1.5	18
87	Patterns of Recurrence in Upper Tract Transitional Cell Carcinoma: Imaging Surveillance. <i>American Journal of Roentgenology</i> , 2016, 207, 789-796.	2.2	6
88	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	1.6	70
89	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711.	1.6	74
90	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. <i>European Urology</i> , 2016, 70, 837-845.	1.9	178

#	ARTICLE	IF	CITATIONS
91	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Journal of Urology, 2016, 195, 399-405.	0.4	8
92	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	7.1	94
93	The impact of histological variants on bladder cancer survival: A population-based analysis.. Journal of Clinical Oncology, 2016, 34, 458-458.	1.6	1
94	Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. Journal of Clinical Oncology, 2016, 34, 306-306.	1.6	0
95	Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. Journal of Clinical Oncology, 2016, 34, 588-588.	1.6	0
96	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 442-442.	1.6	0
97	Diagnosis of Bladder Carcinoma. Surgical Pathology Clinics, 2015, 8, 677-685.	1.7	17
98	Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 383.e9-383.e16.	1.6	24
99	New Trends in the Surgical Management of Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 253-269.	2.2	9
100	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	2.5	36
101	Role of imaging in testicular cancer:Âcurrent and future practice. Future Oncology, 2015, 11, 2575-2586.	2.4	17
102	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	1.6	21
103	The association between nerve sparing and a positive surgical margin during radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e1-18.e6.	1.6	55
104	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal, 2015, 9, 207.	0.6	13
105	The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. Journal of Clinical Oncology, 2015, 33, 414-414.	1.6	0
106	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. Journal of Clinical Oncology, 2015, 33, e17528-e17528.	1.6	0
107	Predicting the Gleason sum of a patient with a prostate biopsy core Gleason 7 and a prostate biopsy core Gleason 8. Canadian Urological Association Journal, 2014, 8, 476.	0.6	0
108	5Î±-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1301.	5.1	38

#	ARTICLE	IF	CITATIONS
109	Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e19-52.e25.	1.6	68
110	Clinical features of leiomyosarcoma of the urinary bladder: Analysis of 183 cases. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 958-965.	1.6	30
111	Reply from Authors re: David Margel. Metformin to Prevent Prostate Cancer: A Call to Unite. Eur Urol 2014;66:1021â€“2. European Urology, 2014, 66, 1022-1023.	1.9	2
112	Positive Surgical Margins After Radical Prostatectomy: Does It Matter?. European Urology, 2014, 65, 314-315.	1.9	8
113	Metformin Use and Prostate Cancer Risk. European Urology, 2014, 66, 1012-1020.	1.9	109
114	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2014, 32, 4576-4576.	1.6	4
115	Diagnostic tests in urology: magnetic resonance imaging (<scp>MRI</scp>) for the staging of prostate cancer. BJU International, 2013, 111, 514-517.	2.5	3
116	Testicular Cancer: What the Radiologist Needs to Know. American Journal of Roentgenology, 2013, 200, 1215-1225.	2.2	87